Brief: Metacrine Achieves Full Enrollment For Met409 Phase 2A Combination Trial In Patients With Type 2 Diabetes And Nash
02/06/2021 13:17
June 2 (Reuters) - Metacrine, Inc. MTCR.O :
* METACRINE ACHIEVES FULL ENROLLMENT FOR MET409 PHASE 2A
COMBINATION TRIAL IN PATIENTS WITH TYPE 2 DIABETES AND NASH
* METACRINE, INC. - TOPLINE DATA EXPECTED TO BE REPORTED IN
Q4 OF
2021
Source text for Eikon: ID:nGNX8yBL8M
Further company coverage: MTCR.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Metacrine
See all newsMetacrine Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Metacrine - Filed Certificate Of Dissolution With Secretary Of State Of State Of Delaware To Effect Complete Liquidation And Dissolution Of Company
Brief: Metacrine Inc Common Stock Will Be Delisted From Nasdaq
Brief: Metacrine Inc- On Jan 31, Received Notice Of Delisting Or Failure To Satisfy Continued Listing Rule Or Standard From Nasdaq
Brief: Metacrine CEO Preston Klassen Was Terminated From All Positions